NUCLEOBINDIN I VARIANT PROTEIN COMPOSITIONS AND METHODS OF USE
The invention relates to Nucleobindin-1 (NUCBl) protein variants that are capable of disaggregating amyloid fibrils as well as inhibiting the formation of fibrils in the presence of physiological concentrations of calcium. Isolated NUCBl protein variants, nucleic acids encoding the protein variants,...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | KAPOOR, NEERAJ GUPTA, RUCHI MENON, SANTOSH, T RALEIGH, DAN SAKMAR, THOMAS |
| description | The invention relates to Nucleobindin-1 (NUCBl) protein variants that are capable of disaggregating amyloid fibrils as well as inhibiting the formation of fibrils in the presence of physiological concentrations of calcium. Isolated NUCBl protein variants, nucleic acids encoding the protein variants, cells comprising the isolated nucleic acids, pharmaceutical compositions and kits comprising the variants, methods of making the variants, and therapeutic uses of the variants are provided.
La présente invention concerne des variants de la protéine nucléobindine 1 (NUCB1) qui sont capables de désagréger les fibrilles d'amyloïde et d'inhiber la formation de fibrilles en présence de concentrations physiologiques de calcium. La présente invention concerne en outre des variants de protéine NUCB1 isolés, des acides nucléiques codant pour les variants de protéine, des cellules comprenant les acides nucléiques isolés, des compositions pharmaceutiques et des kits comprenant les variants, des procédés de préparation des variants, et des utilisations thérapeutiques des variants. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2010009330A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2010009330A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2010009330A13</originalsourceid><addsrcrecordid>eNrjZLDzC3X2cfV38vRz8fRT8FQIcwzydPQLUQgI8g9xBYo4-_sG-Ad7hnj6-wUrOPq5KPi6hnj4uwQr-LsphAa78jCwpiXmFKfyQmluBmU31xBnD93Ugvz41OKCxOTUvNSS-HB_IwNDAwMDS2NjA0dDY-JUAQAMjisC</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>NUCLEOBINDIN I VARIANT PROTEIN COMPOSITIONS AND METHODS OF USE</title><source>esp@cenet</source><creator>KAPOOR, NEERAJ ; GUPTA, RUCHI ; MENON, SANTOSH, T ; RALEIGH, DAN ; SAKMAR, THOMAS</creator><creatorcontrib>KAPOOR, NEERAJ ; GUPTA, RUCHI ; MENON, SANTOSH, T ; RALEIGH, DAN ; SAKMAR, THOMAS</creatorcontrib><description>The invention relates to Nucleobindin-1 (NUCBl) protein variants that are capable of disaggregating amyloid fibrils as well as inhibiting the formation of fibrils in the presence of physiological concentrations of calcium. Isolated NUCBl protein variants, nucleic acids encoding the protein variants, cells comprising the isolated nucleic acids, pharmaceutical compositions and kits comprising the variants, methods of making the variants, and therapeutic uses of the variants are provided.
La présente invention concerne des variants de la protéine nucléobindine 1 (NUCB1) qui sont capables de désagréger les fibrilles d'amyloïde et d'inhiber la formation de fibrilles en présence de concentrations physiologiques de calcium. La présente invention concerne en outre des variants de protéine NUCB1 isolés, des acides nucléiques codant pour les variants de protéine, des cellules comprenant les acides nucléiques isolés, des compositions pharmaceutiques et des kits comprenant les variants, des procédés de préparation des variants, et des utilisations thérapeutiques des variants.</description><language>eng ; fre</language><subject>CHEMISTRY ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES</subject><creationdate>2010</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100121&DB=EPODOC&CC=WO&NR=2010009330A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100121&DB=EPODOC&CC=WO&NR=2010009330A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KAPOOR, NEERAJ</creatorcontrib><creatorcontrib>GUPTA, RUCHI</creatorcontrib><creatorcontrib>MENON, SANTOSH, T</creatorcontrib><creatorcontrib>RALEIGH, DAN</creatorcontrib><creatorcontrib>SAKMAR, THOMAS</creatorcontrib><title>NUCLEOBINDIN I VARIANT PROTEIN COMPOSITIONS AND METHODS OF USE</title><description>The invention relates to Nucleobindin-1 (NUCBl) protein variants that are capable of disaggregating amyloid fibrils as well as inhibiting the formation of fibrils in the presence of physiological concentrations of calcium. Isolated NUCBl protein variants, nucleic acids encoding the protein variants, cells comprising the isolated nucleic acids, pharmaceutical compositions and kits comprising the variants, methods of making the variants, and therapeutic uses of the variants are provided.
La présente invention concerne des variants de la protéine nucléobindine 1 (NUCB1) qui sont capables de désagréger les fibrilles d'amyloïde et d'inhiber la formation de fibrilles en présence de concentrations physiologiques de calcium. La présente invention concerne en outre des variants de protéine NUCB1 isolés, des acides nucléiques codant pour les variants de protéine, des cellules comprenant les acides nucléiques isolés, des compositions pharmaceutiques et des kits comprenant les variants, des procédés de préparation des variants, et des utilisations thérapeutiques des variants.</description><subject>CHEMISTRY</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2010</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLDzC3X2cfV38vRz8fRT8FQIcwzydPQLUQgI8g9xBYo4-_sG-Ad7hnj6-wUrOPq5KPi6hnj4uwQr-LsphAa78jCwpiXmFKfyQmluBmU31xBnD93Ugvz41OKCxOTUvNSS-HB_IwNDAwMDS2NjA0dDY-JUAQAMjisC</recordid><startdate>20100121</startdate><enddate>20100121</enddate><creator>KAPOOR, NEERAJ</creator><creator>GUPTA, RUCHI</creator><creator>MENON, SANTOSH, T</creator><creator>RALEIGH, DAN</creator><creator>SAKMAR, THOMAS</creator><scope>EVB</scope></search><sort><creationdate>20100121</creationdate><title>NUCLEOBINDIN I VARIANT PROTEIN COMPOSITIONS AND METHODS OF USE</title><author>KAPOOR, NEERAJ ; GUPTA, RUCHI ; MENON, SANTOSH, T ; RALEIGH, DAN ; SAKMAR, THOMAS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2010009330A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2010</creationdate><topic>CHEMISTRY</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><toplevel>online_resources</toplevel><creatorcontrib>KAPOOR, NEERAJ</creatorcontrib><creatorcontrib>GUPTA, RUCHI</creatorcontrib><creatorcontrib>MENON, SANTOSH, T</creatorcontrib><creatorcontrib>RALEIGH, DAN</creatorcontrib><creatorcontrib>SAKMAR, THOMAS</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KAPOOR, NEERAJ</au><au>GUPTA, RUCHI</au><au>MENON, SANTOSH, T</au><au>RALEIGH, DAN</au><au>SAKMAR, THOMAS</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>NUCLEOBINDIN I VARIANT PROTEIN COMPOSITIONS AND METHODS OF USE</title><date>2010-01-21</date><risdate>2010</risdate><abstract>The invention relates to Nucleobindin-1 (NUCBl) protein variants that are capable of disaggregating amyloid fibrils as well as inhibiting the formation of fibrils in the presence of physiological concentrations of calcium. Isolated NUCBl protein variants, nucleic acids encoding the protein variants, cells comprising the isolated nucleic acids, pharmaceutical compositions and kits comprising the variants, methods of making the variants, and therapeutic uses of the variants are provided.
La présente invention concerne des variants de la protéine nucléobindine 1 (NUCB1) qui sont capables de désagréger les fibrilles d'amyloïde et d'inhiber la formation de fibrilles en présence de concentrations physiologiques de calcium. La présente invention concerne en outre des variants de protéine NUCB1 isolés, des acides nucléiques codant pour les variants de protéine, des cellules comprenant les acides nucléiques isolés, des compositions pharmaceutiques et des kits comprenant les variants, des procédés de préparation des variants, et des utilisations thérapeutiques des variants.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2010009330A1 |
| source | esp@cenet |
| subjects | CHEMISTRY METALLURGY ORGANIC CHEMISTRY PEPTIDES |
| title | NUCLEOBINDIN I VARIANT PROTEIN COMPOSITIONS AND METHODS OF USE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T11%3A12%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KAPOOR,%20NEERAJ&rft.date=2010-01-21&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2010009330A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |